This article is more than 5 years old. Information may no longer be current.

Sirion Therapeutics merges with Systera to develop dry AMD drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TAMPA, Fla. — Sirion Therapeutics Inc. has merged with Systera Inc., a biopharmaceuticals firm based in La Jolla, Calif., Sirion announced in a press release.

Through the merger, Sirion obtains ST-602, an oral compound that is aimed to reduce ocular lipofuscin accumulation. It has been hypothesized that accumulation of lipofuscin in the eye may be responsible for vision loss in dry age-related macular degeneration, geographic atrophy and other diseases.

Sirion plans to initiate phase 2 proof-of-concept clinical trials of the compound later this year, according to the release.